LOS ANGELES, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 23, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Flywire Corporation (“Flywire” or the “Company”) (NASDAQ: FLYW) securities between February 28, 2024 and February 25, 2025, inclusive (the “Class Period”).

LOS ANGELES , Sept. 2, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST).

LOS ANGELES, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 26, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lockheed Martin Corporation (“Lockheed Martin” or the “Company”) (NYSE: LMT) securities between January 23, 2024 and July 21, 2025, inclusive (the “Class Period”).

BENSALEM, Pa. , Sept. 2, 2025 /PRNewswire/ -- The Law Offices of Howard G.

BENSALEM, Pa. , Sept. 2, 2025 /PRNewswire/ -- The Law Offices of Howard G.

BENSALEM, Pa. , Sept. 2, 2025 /PRNewswire/ -- The Law Offices of Howard G.

Shareholders with losses of $100,000 or more are encouraged to contact the firm. LOS ANGELES , Sept.

LOS ANGELES , Sept. 2, 2025 /PRNewswire/ -- The Law Offices of Frank R.

LOS ANGELES , Sept. 2, 2025 /PRNewswire/ -- The Law Offices of Frank R.

ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO). The lawsuit alleges that throughout the Class Period, and in the Company's Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Alto's business, operations, and prospects, including allegations that: (i) ALTO-100 was less effective in treating MDD than Defendants had led investors to believe; (ii) accordingly, ALTO-100's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Alto's business and/or financial prospects were overstated.

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Nutex Health Inc. (NASDAQ: NUTX) between August 8, 2024 and August 14, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 21, 2025.

Kraft Heinz Co (NASDAQ:KHC, ETR:KHNZ) shares fell almost 7% on Tuesday after it announced plans to divide into two separate, publicly traded companies, marking a reversal of the 2015 merger that created the current food conglomerate. The separation, expected to be completed in the second half of 2026, comes after years of challenges for Kraft Heinz, including declining sales and changing consumer preferences toward healthier and more affordable options.

MO's on! shipments jumped 26.5% in the second quarter, lifting its U.S. pouch share as marketing and earnings momentum intensify in a fast-growing market.

GLD hits a 52-week high as safe-haven demand, inflation fears and rate cut expectations fuel gold's rally.

Target Hospitality Corp. still experiences the impact of contract cancellations, but financial resilience is evident. Its decent liquidity ensures it can sustain its increasing capacity and debt repayments while covering new capex. Its new contracts can strengthen its performance in the coming years and support its upside.

Douglas Emmett is an office REIT focused on California and Hawaii. The company also operates a multifamily portfolio, which has recently grown in significance. Q2 2025 FFO remained weaker Y/Y due to higher interest costs, elevated taxes, and persistent office market weakness. Fed rate cuts should result in a near-term reduction in interest expenses, although swap expirations later in 2026 will likely push interest costs in 2027 back to 2025 levels.

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.

TSLA trims Model 3 prices in China as demand weakens and competition from BYD and others intensifies.

ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor's four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.

I rate VOE as a hold, given its fair valuation and mixed technical signals despite recent upward momentum. VOE offers diversified mid-cap value exposure with low expenses and a higher yield than the S&P 500, but growth prospects are modest. The ETF's sector allocation favors Financials and Industrials, with limited tech exposure, which could help if tech underperforms.